Francesco Sbrana, Mascia Pianelli, Roberta Luciani, Federico Bigazzi, Carmen Corciulo, Andrea Ripoli, Tiziana Sampietro, Beatrice Dal Pino
BACKGROUND: Despite advance in pharmacotherapy of lipid disorders, lipoprotein apheresis (LA) plays a leading role in the management of severe hypercholesterolemia and in atherosclerosis prevention. METHODS: Aim of this study was to retrospectively evaluate Charlson Comorbidity Index (CCI), presence of major comorbidity, and/or concomitant polypharmacy (definite as 5+ drugs daily) in patients with inherited dyslipidemias on chronic LA. RESULTS: Since 1994, we performed more than 500 LA treatment/year and followed a total of 83 patients (age 56 [47-65] years, male 75%)...
October 19, 2023: Journal of Clinical Apheresis